The estimated Net Worth of Edwin Jonathan Tucker is at least $1.94 millió dollars as of 29 September 2021. Mr. Tucker owns over 1,364 units of Mirum Pharmaceuticals Inc stock worth over $1,918,137 and over the last 5 years he sold MIRM stock worth over $26,271. In addition, he makes $0 as Chief Medical Officer at Mirum Pharmaceuticals Inc.
Edwin has made over 5 trades of the Mirum Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,364 units of MIRM stock worth $26,271 on 29 September 2021.
The largest trade he's ever made was exercising 25,000 units of Mirum Pharmaceuticals Inc stock on 30 October 2020 worth over $192,500. On average, Edwin trades about 3,283 units every 51 days since 2019. As of 29 September 2021 he still owns at least 45,768 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Mr. Tucker stock trades at the bottom of the page.
Edwin Tucker serves as Chief Medical Officer of the Company. Previously, from 2018 to 2019, Dr. Tucker served as Chief Operating Officer at Acerta Pharma LLC (“Acerta”). Prior to Acerta, from 2015 and 2018, Dr. Tucker was Senior Vice President of Clinical Development, Medical Safety, Corporate Compliance and Quality at Acerta helping to transform a small biotechnology startup into a post-approval entity. Prior to joining Acerta, Dr. Tucker was Vice President, Global Safety at Roche/Genentech, a biotechnology company, between 2013 and 2015 and Vice President, Global Safety at Johnson & Johnson, between 2010 and 2013. Prior to joining Johnson & Johnson, Dr. Tucker served in multiple clinical development roles at Bayer HealthCare in the United Kingdom and United States. He held several medical posts with the National Health Service in the United Kingdom from 1996 to 2000. Dr. Tucker is a member of the Royal College of Physicians (U.K.) and received an MBA from the University of Connecticut. Dr. Tucker received degrees in pharmacology and medicine from the University of Leeds, United Kingdom.
Edwin Tucker is 48, he's been the Chief Medical Officer of Mirum Pharmaceuticals Inc since 2019. There are 13 older and 5 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
Edwin's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell és Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: